| 1 |
29201198 | Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. | 2017 Nov |
2 |
| 2 |
24288364 | Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes. | 2015 Jan |
1 |
| 3 |
25514794 | Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. | 2015 Apr 1 |
1 |
| 4 |
23600368 | Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. | 2013 Jul |
2 |
| 5 |
23949918 | Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions. | 2013 Oct |
1 |
| 6 |
24125402 | Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. | 2013 Nov |
2 |
| 7 |
22419750 | Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. | 2012 May |
2 |
| 8 |
23118302 | Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy. | 2012 Dec |
1 |
| 9 |
21352079 | Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂. | 2011 Jun |
2 |
| 10 |
21714585 | The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. | 2011 Dec |
1 |
| 11 |
17656665 | Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. | 2007 Oct |
2 |